Skin testing with bendamustine: what concentration should be used?

We present a case of the patient, who developed hypersensitivity reaction during the treatment of chronic lymphocytic leukemia. Bendamustine was suspected as a culprit agent. The patient as well as 3 controls underwent skin testing with the concentrations of the bendamustine described in earlier stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Malinauskiene, Laura, Cerniauskas, Kestutis, Linauskiene, Kotryna, Griguola, Linas, Chomiciene, Anzelika, Blaziene, Audra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491343/
https://www.ncbi.nlm.nih.gov/pubmed/32944028
http://dx.doi.org/10.1186/s13223-020-00469-3
_version_ 1783582202974437376
author Malinauskiene, Laura
Cerniauskas, Kestutis
Linauskiene, Kotryna
Griguola, Linas
Chomiciene, Anzelika
Blaziene, Audra
author_facet Malinauskiene, Laura
Cerniauskas, Kestutis
Linauskiene, Kotryna
Griguola, Linas
Chomiciene, Anzelika
Blaziene, Audra
author_sort Malinauskiene, Laura
collection PubMed
description We present a case of the patient, who developed hypersensitivity reaction during the treatment of chronic lymphocytic leukemia. Bendamustine was suspected as a culprit agent. The patient as well as 3 controls underwent skin testing with the concentrations of the bendamustine described in earlier studies. We doubted the testing recommendations as all the controls developed serious local reactions. The clinical meaning of the positive skin test reaction in the patient remained unclear and questioned the safeness of recommended testing concentrations as in certain situations wrong diagnosis could be made or even harm could be done. Future investigations are needed when allergy to bendamustine is suspected.
format Online
Article
Text
id pubmed-7491343
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74913432020-09-16 Skin testing with bendamustine: what concentration should be used? Malinauskiene, Laura Cerniauskas, Kestutis Linauskiene, Kotryna Griguola, Linas Chomiciene, Anzelika Blaziene, Audra Allergy Asthma Clin Immunol Letter to the Editor We present a case of the patient, who developed hypersensitivity reaction during the treatment of chronic lymphocytic leukemia. Bendamustine was suspected as a culprit agent. The patient as well as 3 controls underwent skin testing with the concentrations of the bendamustine described in earlier studies. We doubted the testing recommendations as all the controls developed serious local reactions. The clinical meaning of the positive skin test reaction in the patient remained unclear and questioned the safeness of recommended testing concentrations as in certain situations wrong diagnosis could be made or even harm could be done. Future investigations are needed when allergy to bendamustine is suspected. BioMed Central 2020-07-30 /pmc/articles/PMC7491343/ /pubmed/32944028 http://dx.doi.org/10.1186/s13223-020-00469-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Letter to the Editor
Malinauskiene, Laura
Cerniauskas, Kestutis
Linauskiene, Kotryna
Griguola, Linas
Chomiciene, Anzelika
Blaziene, Audra
Skin testing with bendamustine: what concentration should be used?
title Skin testing with bendamustine: what concentration should be used?
title_full Skin testing with bendamustine: what concentration should be used?
title_fullStr Skin testing with bendamustine: what concentration should be used?
title_full_unstemmed Skin testing with bendamustine: what concentration should be used?
title_short Skin testing with bendamustine: what concentration should be used?
title_sort skin testing with bendamustine: what concentration should be used?
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491343/
https://www.ncbi.nlm.nih.gov/pubmed/32944028
http://dx.doi.org/10.1186/s13223-020-00469-3
work_keys_str_mv AT malinauskienelaura skintestingwithbendamustinewhatconcentrationshouldbeused
AT cerniauskaskestutis skintestingwithbendamustinewhatconcentrationshouldbeused
AT linauskienekotryna skintestingwithbendamustinewhatconcentrationshouldbeused
AT griguolalinas skintestingwithbendamustinewhatconcentrationshouldbeused
AT chomicieneanzelika skintestingwithbendamustinewhatconcentrationshouldbeused
AT blazieneaudra skintestingwithbendamustinewhatconcentrationshouldbeused

Ejemplares similares